The Keck School of Medicine of USC and the USC Viterbi School of Engineering have announced that the Alfred E. Mann Department of Biomedical Engineering will become a joint department between the two schools, forging a formal partnership in education, research and innovation in technology and medicine. This joint department, one of the first of its kind in California, builds on decades of cross-disciplinary research and breakthroughs at USC, including the world’s first FDA-approved artificial retina, the first brain implant to restore lost memory function, and innovations in immunotherapy to treat cancer. With added support from USC’s president and provost, the newly integrated biomedical engineering department will create new structures and gain new resources dedicated to further accelerating biomedical innovation, enriching educational programs and advancing technology in medicine. It will combine expertise in priority areas spanning medical devices, neuroengineering, imaging science, drug discovery, artificial intelligence (AI) and informatics, cellular and molecular bioengineering, and more. Facilities at both the Viterbi School of Engineering and the Keck School of Medicine will be devoted to the joint department, with the chair reporting to both deans. Yingxiao (Peter) Wang, PhD, the department’s current chair, who also holds the Dwight C. and Hildagarde E. Baum Chair in Biomedical Engineering, will help implement the transition by leading the department into its next phase.

Understanding how proteins interact with their own mirror images enabled a Kobe University research team to design a small mirror protein that disables a causal factor of Alzheimer’s disease, amyloid-beta.

Apathy can be an early indicator of dementia. Texas A&M researchers are building a digital human that combines screening questions with facial expression analysis and biometric monitoring to identify subtle signals, including apathy.

The article examines the emerging use of genomic testing to predict complex traits in embryos, such as intelligence or the risk of developing conditions like diabetes, heart disease, or Alzheimer’s disease later in life. As embryo testing moves beyond disease prevention toward the prediction of complex human social characteristics, the author argues that stronger oversight and clearer regulations are needed.

Scientists at CityUHK achieved a breakthrough in recent months with the discovery a novel compound, named MF-8. The compound and its associated pharmaceuticals demonstrate significant potential to provide safer, more effective treatments for psychiatric and neurological disorders, such as memory impairment, depression and anxiety, while effectively mitigating the side effects associated with existing medications.